Dendreon Raising $125 Million Via I.P. Sale (DNDN, MRK)

Health and Healthcare

Published: December 6, 2011 12:45 pm

Last Updated: April 27, 2020 8:06 pm

Dendreon Corporation (NASDAQ: DNDN) is supposed to be the king of prostate cancer with its PROVENGE treatment. Unfortunately, PROVENGE sales ran slower than expected after the FDA took forever to approve it and after the Medicare and Medicaid reimbursements took a considerable time.

Now the company has news out that it has agreed to sell its royalty interest related to intellectual property licensed to Merck & Co. Inc. (NYSE: MRK) associated with VICTRELIS under the Schering unit for $125 million in cash.

VICTRELIS is a treatment for chronic hepatitis C as a protease inhibitor. The press release noted that the royalty interest was acquired by CPPIB Credit Investments Inc., a wholly-owned subsidiary of CPP Investment Board (CPPIB).

The intellectual property related to VICTRELIS was co-developed by Corvas International, Inc. and Schering and, was acquired by Dendreon in July 2003. The transaction is expected to close in December 2011.

The move is aimed at strengthening its cash position and to enable the company to further invest in its core business initiatives.

Dendreon shares are flat at $8.80 and its market cap is currently $1.3 billion. To show how bad this one has been, Dendreon’s 52-week trading range is $6.46 to $43.96.

JON C. OGG

Take Charge of Your Retirement In Just A Few Minutes (Sponsor)

Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor.

Here’s how it works:

Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
Choose Your Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.

Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!